PlexusDx vs MEDVi: GLP-1 Pricing and Plan Terms Compared in 2026

Last reviewed: September 8, 2026 Last updated: September 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

MEDVi's ongoing rate for compounded semaglutide injection is $299/month; PlexusDx charges $189/month with no commitment. That $110 monthly gap grows to $1,320 over twelve months, even after accounting for MEDVi's first-month introductory rate of $179. For tirzepatide, the ongoing spread is identical: MEDVi $399/month versus PlexusDx $289 month-to-month, another $1,320 annual difference. MEDVi offers a structured three-tier bundle ladder with 0% financing, a free dietitian visit, and unlimited care coaching; PlexusDx publishes all pricing before intake, holds the same rate at every dose, and offers multi-month commitments that reduce semaglutide to $149/month at the six-month tier. Both programs include the provider visit, medication, and shipping in the stated price; neither charges a separate membership fee for compounded pathways. The decision hinges on whether MEDVi's broader support bundle and payment flexibility outweigh PlexusDx's lower ongoing costs and upfront transparency.

At-a-glance comparison: MEDVi versus PlexusDx

MEDVi pricing captured September 4, 2026 via checkout-verified research. PlexusDx pricing captured July 20, 2026 from published product pages; month-to-month rates confirmed September 8, 2026. Trustpilot data captured September 4, 2026.

Ongoing monthly rates: the core difference

MEDVi charges $299 per month for compounded semaglutide injection refills and $399 per month for compounded tirzepatide. PlexusDx's month-to-month rates are $189 for semaglutide and $289 for tirzepatide—$110 less each month in both cases. At steady state, that $110 monthly delta produces a $1,320 annual savings on the PlexusDx side, assuming identical refill frequency and no interruption.

MEDVi's first-month introductory rate is $179 for semaglutide (with refills at $299) and $279 for tirzepatide (with refills at $399). Over a full twelve-month horizon, the math becomes: Month 1 at the introductory $179 (or $279), then eleven refills at the ongoing $299 (or $399). For semaglutide, that totals $3,468 in year one—an effective average of $289 per month. PlexusDx's flat $189 month-to-month produces $2,268 over the same span, still $1,200 less even after crediting MEDVi's sign-up discount. The same arithmetic holds for tirzepatide: MEDVi year-one total is $4,668 (effective $389/month) versus PlexusDx's $3,468, again a $1,200 difference.

Both figures treat the first-month rate as a one-time event and the ongoing rate as the true recurring cost. If a patient remains on medication for multiple years, the introductory month becomes a smaller fraction of total spend, and the $110 per-refill gap dominates the economic case.

Multi-month commitments and prepayment models

MEDVi offers three-, six-, and twelve-month bundles. The capture noted that "bundles are non-refundable for unused months," which signals an upfront or prepaid structure, though the exact per-month rate within each bundle tier was not published in the sources reviewed. MEDVi also advertises 0% financing through Klarna, spreading payments over twelve months; MEDVi states it is not a party to that financing agreement, meaning the patient contracts directly with Klarna.

PlexusDx operates on a billing-commitment model rather than prepayment. The three-month tier bills $169 per month for semaglutide or $269 for tirzepatide, and the patient is committed to three billing cycles; the six-month tier drops to $149 semaglutide or $249 tirzepatide, with a six-cycle commitment. No funds change hands beyond the current month's charge, and the commitment is a billing obligation rather than a lump sum. Cancellation before the term ends may trigger an early-termination adjustment to the month-to-month rate for months already billed at the discount, but the financial exposure is limited to the difference between the discounted rate already paid and the standard rate, not the full cost of unused future months.

For patients confident in a long runway, MEDVi's longest-available term is forty-eight weeks (twelve months). For patients who want commitment-tier pricing without large upfront outlays, PlexusDx's billing model and published per-month rates offer more visibility into recurring cost.

Twelve-month cost comparison across tiers

All twelve-month totals are our calculation. MEDVi's "effective" rate for the first-month scenario averages one discounted month and eleven standard refills. PlexusDx's commitment tiers are billed monthly at the stated rate; no prepayment required.

Oral route: tablets versus capsules, and the surcharge question

MEDVi offers compounded semaglutide in tablet form at a $70 monthly surcharge over the injection price. That produces a first-month rate of $249 ($179 + $70) and an ongoing rate of $369 ($299 + $70). MEDVi also lists compounded tirzepatide oral; the sources captured tirzepatide pricing without a separate oral surcharge displayed, though it is unclear whether the $399 rate applies uniformly to both injection and oral or whether an undisclosed adjustment exists at checkout.

PlexusDx prices oral semaglutide at $289 month-to-month, $269 at three months, and $249 at six months—rates that sit between the PlexusDx semaglutide injection tiers and the PlexusDx tirzepatide injection tiers. Oral tirzepatide is $349 month-to-month, $299 at three months, and $279 at six months. These are distinct SKUs rather than add-on surcharges, and the oral-versus-injection decision is made at enrollment rather than as a mid-program switch.

For patients who prefer to avoid injections, MEDVi's oral semaglutide at $369 per month ongoing is $80 more than PlexusDx's oral semaglutide at $289 month-to-month, or $120 more than PlexusDx's six-month oral semaglutide rate of $249. The oral route generally commands a premium in the compounding market due to formulation complexity and lower bioavailability, but the size of that premium varies by program.

Included services: coaching depth versus pharmacy check-ins

MEDVi includes unlimited doctor calls, a free dietitian visit, and free care coaching in its base price. The capture confirmed these are part of the all-in package for compounded programs, with no separate line-item charge. That bundle is broader than most telehealth GLP-1 programs offer at the included level.

PlexusDx includes the initial provider visit, medication, and shipping, and offers a free check-in with a Doctor of Pharmacy for program members. PlexusDx also sells an optional DNA testing add-on—$298 standalone or $99 for active members—though the test does not select medication or predict response; the prescribing provider makes that determination independently.

The service-inclusion gap matters most for patients who want structured nutritional guidance or frequent clinician touchpoints without per-session fees. MEDVi's unlimited-call model and dietitian inclusion represent a clear advantage in that dimension. Patients who are self-directed or who already work with an outside dietitian may place less weight on those extras and prioritize medication cost.

Pricing transparency and the pre-intake visibility question

PlexusDx publishes every rate—month-to-month, three-month, six-month—on product pages before intake begins. A prospective patient can calculate twelve-month cost, compare routes (injection versus oral), and evaluate commitment trade-offs without entering personal information.

MEDVi shows pricing after the health questionnaire. The sources captured MEDVi's checkout flow stopping at the results-and-selection page, where the introductory $179 first-month semaglutide rate (with $299 refills) and the introductory $279 first-month tirzepatide rate (with $399 refills) were displayed. That structure is common in telehealth weight loss: intake first, then pricing tied to eligibility. It adds one procedural step but does not obscure the eventual figure; once the questionnaire is complete, the patient sees the rate before payment.

For cost-sensitive comparisons across multiple programs, PlexusDx's upfront publication reduces friction. For patients who want a single-program evaluation and are comfortable with intake-then-price sequencing, MEDVi's model is straightforward once the questionnaire is done.

Choose MEDVi if…

• You want unlimited provider calls, a free dietitian visit, and structured care coaching included without add-on fees, and the value of that support bundle justifies the higher per-month medication cost.
• You prefer a first-month discount to lower the entry cost, and you are comfortable with the jump to the ongoing rate in month two.
• You want access to 0% financing through Klarna to spread payments over twelve months, even though MEDVi is not a party to that financing agreement.
• You are evaluating longer commitment horizons and want the option of a twelve-month (48-week) bundle, understanding that unused months in prepaid bundles are non-refundable.
• You value a larger support team and more frequent touchpoints over the lowest possible medication price.

Choose PlexusDx if…

• You want the lowest ongoing cost for compounded semaglutide or tirzepatide, with month-to-month rates $110 below MEDVi's standard refill price—a difference that grows to $1,320 per year.
• You prefer to see all pricing before you begin intake, with every tier and commitment option published on product pages.
• You want a commitment-tier discount without prepaying a bundle, so each month is billed individually at the reduced rate and no lump sum is at risk if you stop early.
• You prefer a simpler service package—provider visit, medication, shipping, and a pharmacy check-in—without paying for broader coaching infrastructure you may not use.
• You want access to a microdose GLP-1 maintenance option at $129/month after reaching your goal weight, or you are exploring oral routes at prices below MEDVi's injection-plus-surcharge model.

Dose escalation and price stability

Both programs hold the monthly price constant as dose increases. MEDVi states explicitly that "dose increases do not raise price"; PlexusDx operates the same way, with the same rate applying at 0.25 mg semaglutide as at 2.4 mg. That policy is now standard among large compounding telehealth providers, but it remains worth confirming because some smaller programs tier pricing by milligram strength.

For patients who expect to spend months titrating upward—common with GLP-1 receptor agonists to manage gastrointestinal tolerance—a flat-rate structure simplifies budgeting. The monthly cost is the monthly cost, regardless of where the patient sits on the dosing ladder.

Cancellation terms and refund exposure

MEDVi advertises "no contract" and "cancel anytime" for its month-to-month refill path. The sources also state that "bundles are non-refundable for unused months," which means a patient who prepays a six- or twelve-month package and stops early does not receive a prorated refund. That refund policy is typical for prepaid telehealth bundles but does introduce financial risk if a patient cannot tolerate the medication or needs to switch programs mid-term.

PlexusDx's multi-month commitments are billing commitments rather than prepaid packages. A patient on the six-month semaglutide tier pays $149 each month for six months; if the patient cancels in month four, the system has collected four months of charges and no prepaid balance exists to forfeit. Early termination may trigger a retroactive adjustment to the month-to-month rate for the months already billed at the discount, but the financial exposure is limited to the difference between the discounted rate already paid and the standard rate, not the full cost of unused future months.

For risk-averse patients, PlexusDx's billing model reduces the downside of commitment. For patients confident in a long runway and drawn to the lowest possible per-month rate, MEDVi's prepaid bundles may offer a better effective price—if that price is published and favorable—but the refund restriction must be weighed.

Methodology and freshness

MEDVi pricing was captured September 4, 2026 via checkout-verified research, stopping at the results-and-selection page where first-month and ongoing rates were displayed for compounded semaglutide injection ($179 first month, $299 refill), compounded semaglutide tablet ($249 first month, $369 refill), and compounded tirzepatide ($279 first month, $399 refill). Multi-month bundle existence, 0% financing, included services (unlimited doctor calls, free dietitian visit, care coaching), and cancellation terms (no contract, cancel anytime, bundles non-refundable for unused months) were documented from MEDVi's homepage and program-description pages captured July 20, 2026 and September 4, 2026. No source conflict existed; all ongoing rates were consistent across capture dates.

PlexusDx pricing was captured July 20, 2026 from published product pages and confirmed September 8, 2026. Month-to-month, three-month, and six-month rates are public before intake. Included services, dose-price policy, and cancellation terms were documented from PlexusDx's FAQ and product pages captured July 20, 2026. PlexusDx Trustpilot rating (4.3 stars, 79% five-star, 83% four-star-or-higher) was captured September 9, 2026.

All twelve-month cost totals and effective monthly averages are our calculation, derived by multiplying stated monthly rates by twelve or by summing one first-month rate and eleven standard refills. No competitor bundle per-month rate was published in the sources, so MEDVi multi-month pricing is described structurally (terms up to forty-eight weeks, 0% financing available) but not quantified. Where we write "effective monthly average" for MEDVi's first-month scenario, we are dividing the year-one total by twelve to show the blended cost; that figure is our calculation, not a rate MEDVi advertises.

Compounded medications are not FDA-approved. The FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies. Neither program guarantees eligibility, medication selection, dose, or clinical outcome.

Frequently Asked Questions

Is MEDVi's $179 first-month semaglutide price the true ongoing cost?

No. The $179 figure is a first-month introductory rate; refills are $299 per month. Over twelve months, the effective average is $289 per month when you include one discounted month and eleven standard refills. The $299 ongoing rate is the relevant figure for long-term budgeting.

Does PlexusDx require a multi-month commitment to get the lowest price?

Yes. PlexusDx's lowest semaglutide rate—$149 per month—requires a six-month billing commitment. The month-to-month rate is $189, and the three-month rate is $169. Each tier is billed monthly; no upfront lump sum is required, and no prepaid balance is at risk if you stop early.

Do both programs include the provider visit and medication in the advertised price?

Yes. MEDVi's $299 semaglutide and $399 tirzepatide rates include the consultation, prescription, medication, and shipping, plus unlimited doctor calls, a free dietitian visit, and care coaching. PlexusDx's rates include the provider visit, medication, shipping, and a free pharmacy check-in. Neither program charges a separate membership fee for compounded pathways.

Can I switch from injection to oral mid-program, and does the price change?

The route is typically chosen at enrollment. MEDVi charges a $70 monthly surcharge for semaglutide tablets over the injection price; tirzepatide oral pricing was listed but a surcharge was not explicitly displayed. PlexusDx treats oral semaglutide and oral tirzepatide as separate products with their own rate cards. Switching routes mid-program generally requires a new prescription and may restart the commitment clock.

What happens if I prepay a MEDVi bundle and need to stop early?

MEDVi states that "bundles are non-refundable for unused months." If you prepay a six- or twelve-month package and stop in month three, you will not receive a prorated refund for the remaining months. Month-to-month subscriptions can be canceled anytime without forfeiting prepaid funds, because no prepayment occurs.

Sources

• MEDVi homepage and program-description pages (captured July 20, 2026 and September 4, 2026) – service inclusions, multi-month bundles, 0% financing, cancellation terms
• MEDVi checkout-verified research dataset (captured September 4, 2026) – first-month and ongoing rates for compounded semaglutide injection, semaglutide tablet, and tirzepatide; supply duration; all-in confirmation
• PlexusDx product pages (captured July 20, 2026; confirmed September 8, 2026) – month-to-month, three-month, and six-month rates for semaglutide injection, tirzepatide injection, semaglutide oral, tirzepatide oral, and microdose GLP-1
• PlexusDx FAQ and service-description pages (captured July 20, 2026) – included services, dose-price policy, cancellation terms, DNA testing add-on pricing
• PlexusDx Trustpilot profile (captured September 4, 2026) – 4.3-star rating, review-distribution percentages

Compounded medication disclosure: Compounded medications are not FDA-approved. The FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.